Alchemedicine Inc. is a biotechnology company specializing in small‑molecule drug discovery and medicinal chemistry. It focuses on discovering, designing, and optimizing novel compounds and advancing early candidates toward clinical development.
The company follows a collaboration‑driven model, providing proprietary leads and platform‑based chemistry to pharmaceutical partners through research alliances and licensing agreements. Its work supports the development of new therapies across multiple disease areas by integrating high‑throughput synthesis, compound profiling, and data‑guided design within the pharmaceutical R&D value chain.
The agreement grants exclusive rights to develop preclinical compounds for autoimmune diseases, marking a deepened partnership and strategic alignment.
AK1960, a novel ETA receptor antagonist with a new core structure, shows high ETA selectivity and kidney-disease efficacy in animals and has advanced to Phase I for refractory diseases.
AK1960, an ETA receptor antagonist, enters Phase I trials for refractory diseases, leveraging Alchemedicine's HiSAP™ platform and partnerships with Calliditas and Veloxis.
AK1960, a selective endothelin A receptor antagonist, shows promise for treating refractory kidney diseases, aligning with R&D strategies for unmet medical needs.
Asahi Kasei Pharma gains global rights to develop and commercialize HiSAP compounds, with Alchemedicine receiving up to ¥41.3 billion in payments and royalties.
